# AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Canonical URL: https://biopharmsignal.com/news/ANGO/angiodynamics-receives-fda-ide-approval-for-relief-feasibility-study-evaluating-nanoknife-ire-platform-as-minimally-invasive-treatment-for-benign-prostatic-hyperplasia-bph
Ticker: ANGO
Company: AngioDynamics
Source: AngioDynamics
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.angiodynamics.com
## Summary

Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 17, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow

## Article Body
Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 17, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow
## Recent Company News
- 2026-06-30 12:00 EST — [AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026](https://biopharmsignal.com/news/ANGO/angiodynamics-to-report-fiscal-2026-fourth-quarter-and-full-year-financial-resul-d0a55e66) — Source: AngioDynamics
- 2026-06-25 13:46 EST — [AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)](https://biopharmsignal.com/news/ANGO/angiodynamics-receives-fda-ide-approval-for-relief-feasibility-study-evaluating-nanoknife-ire-platform-as-minimally-invasive-treatment-for-benign-prostatic-hyperplasia-bph) — Source: AngioDynamics
- 2026-06-25 13:46 EST — [AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect](https://biopharmsignal.com/news/ANGO/angiodynamics-expands-patient-access-to-nanoknife-ire-for-prostate-and-liver-cancer-as-medicare-coverage-framework-takes-effect) — Source: AngioDynamics
- 2026-06-25 13:46 EST — [AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: AngioDynamics
- 2026-06-25 13:46 EST — [AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer](https://biopharmsignal.com/news/ANGO/angiodynamics-announces-two-year-preserve-trial-data-demonstrating-durable-nanoknife-ire-system-outcomes-in-intermediate-risk-prostate-cancer) — Source: AngioDynamics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)